Regulus (RGLS): Long-Term Debt to Capital Ratio

Brandmark of Regulus (RGLS)

This chart of Regulus Therapeutics (RGLS) stock quotes reflects the dynamics of a company striving for global leadership in the renal pathology drug segment through the expansion of RGLS8429 clinical trials, with the indicator standing at 0.02. Long-term laboratory agreements and the diversification of component supplies ensure process stability. The business is based on advanced methods of targeting intracellular molecules for brain and kidney therapy.

RGLS - Regulus Therapeutics, Inc. Long-Term Debt to Equity over the range 07/04/2022 - 07/05/2025

Regulus Therapeutics - analytical breakdowns and key metrics (RGLS)

- price and consensus price forecast:
Share Price Regulus Therapeutics, Inc.|RGLS - Price Target Chart
- market capitalization data:
Market Capitalization Regulus Therapeutics Inc.|RGLS - Enterprise Value
- book capitalization data:
Book Value per Share Regulus Therapeutics|RGLS - Company Book Value|Market Value to Book Value regulusrx.com|RGLS - Company Total Assets
- debt and liquidity data:
Debt to Capital Regulus Therapeutics|RGLS - Long-Term Debt to Capital|Short-Term Indebtedness to Equity regulusrx.com|RGLS - Company Total Debt|Debts to Book Capitalization Regulus Therapeutics Inc.
Summary company analysis:Regulus Therapeutics, Inc.
Core merchandise of Regulus Therapeutics

To objectively assess the operational resilience of Regulus Therapeutics (RGLS), investors must monitor the structure of borrowed capital. This long-term financial dependency ratio reflects the relationship between loans with a maturity exceeding one year and equity. An increase in this metric indicates a rising credit burden and risks of destabilization. This is critical for the biotechnology sector, as the development of RNA drugs requires massive investments. Strategic partnerships for Regulus Therapeutics (RGLS) help reduce debt dependency by ensuring resource synergy.

Analysis of competing companies

Long-Term Debt to Capital Ratio TEM|Long-Term Debt to Equity Qiagen Group QGEN|Long-Term Debt to Capital Ratio Isis Pharmaceuticals (IONS)|Long-Term Debt to Capital RGEN (Repligen Corporation)|aviditybiosciences.com - Long-Term Debt to Capital|Long-Term Debt to Equity CRISPR Therapeutics (CRSP)|WGS - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital RARE|Beam Tx (BEAM) - Long-Term Liabilities to Capital|Sarepta Therapeutics, Inc. - Long-Term Debt to Capital|Long-Term Indebtedness to Equity twistbioscience.com (TWST)|Long-Term Debt to Equity Ratio TXG|Long-Term Debt to Capital NTLA (Intellia Therapeutics Inc)|Long-Term Debt to Equity Stoke STOK|BLFS - Long-Term Debt to Equity|Wave Life Sciences - Long-Term Debt to Equity Ratio|MAZE: Long-Term Debt to Capital|Sionna Therapeutics - Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital Prime Medicine Inc|TSHA - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient uniQure Pharma (QURE)|Long-Term Debt to Equity Ratio MeiraGTx Holdings plc|Long-Term Loans to Capital Ratio regenxbio.com (RGNX)|Long-Term Debt to Capital Solid Biosciences|Long-Term Debt to Capital Coefficient Ocugen Inc OCGN|PACB (Pacific Biosciences of California) - Long-Term Debt to Capital|BNTC: Long-Term Liabilities to Capital|Long-Term Debt to Equity Design Therapeutics DSGN|rocketpharma.com (RCKT) - Long-Term Debt to Capital Coefficient|FDMT (4D Molecular Therapeutics, Inc.) - Long-Term Debt to Capital|Long-Term Debt to Capital LXEO|KRRO - Long-Term Debt to Equity|Long-Term Liabilities to Equity Editas Corp (EDIT)|SLN: Long-Term Debt to Capital|PRQR - Long-Term Liabilities to Capital|Codexis Bio - Long-Term Debt to Equity Ratio|Sangamo Therapeutics Inc. (SGMO) - Long-Term Debt to Capital|NAUT - Long-Term Debt to Equity Ratio|Metagenomi Therapeutics (MGX) - Long-Term Loans to Capital Ratio|DTIL: Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Generation Bio Corp|Long-Term Debt to Capital BOLD (Boundless Bio)|Long-Term Debt to Equity Ratio XCUR (exicuretx.com)|Long-Term Debt to Equity IMNN|Phio Pharmaceuticals Corp - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Mustang Bio Corp (MBIO)|RNAZ - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital BNGO (bionanogenomics.com)|APDN (Applied DNA Sciences Inc) - Long-Term Indebtedness to Equity|Long-Term Debt to Equity Bluebird Bio|Long-Term Debt to Equity IPA|OMGA (Omega Therapeutics) - Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital singulargenomics.com (OMIC)|SYRS - Long-Term Debt to Capital|Telesis Bio Inc. - Long-Term Debt to Capital Ratio|TRACON (TCON) - Long-Term Debt to Equity|UBX - Long-Term Debt to Capital Ratio